SINGAPORE, Feb. 4, 2026 /PRNewswire/ — This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulationSINGAPORE, Feb. 4, 2026 /PRNewswire/ — This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation

Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.

2 min read

SINGAPORE, Feb. 4, 2026 /PRNewswire/ — This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurological disorders.

Empowered By Evidence (EBE) is an independent, international non-profit organisation, founded in 2014 and based in New York. Its panel of natural health specialists and researchers applies a transparent, science-led process to evaluate natural health products, helping healthcare professionals and their patients make evidence-based decisions. Independent assessors evaluate each product, with no association to the product or its competitors, ensuring objectivity.

Nigel Pollard, Chair of the Board of Directors of EBE, remarked:

“Independent advice, education, and clear product-specific evidence help people make confident, informed choices. Our independent product accreditation is an easy way to find exact products like NeuroAiD™II that can deliver results shown in specific clinical trials.”

EBE helps healthcare professionals and consumers choose natural health products supported by rigorous clinical evidence.

David Picard, CEO of Moleac, commented:

“We are proud to be recognised by the prestigious EBE, a well-respected, independent non-profit. This is a testament to the work we conducted at Moleac over the years—pioneering an innovative approach to develop a complex herbal formulation, supported by a unique standardised proprietary manufacturing process to ensure the consistency and validity of its safety and clinical properties, as documented in over 90 publications.”

For more information on Empowered By Evidence, please visit www.empoweredbyevidence.org

About Moleac

Moleac is a biopharmaceutical company that stays committed to helping patients and their families reconnect with their lives. We address unmet needs of patients suffering a loss of brain function after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. We select scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties, and make them available internationally.

For further information, visit moleac.com

Cision View original content:https://www.prnewswire.com/news-releases/moleac-is-pleased-to-announce-that-neuroaidii-has-been-awarded-gold-accreditation-by-empowered-by-evidence-302679661.html

SOURCE Moleac

Market Opportunity
4 Logo
4 Price(4)
$0.01034
$0.01034$0.01034
-8.65%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin Pushes Ethereum Builders to Move Beyond Clone Chains

Vitalik Buterin Pushes Ethereum Builders to Move Beyond Clone Chains

Vitalik Buterin has warned Ethereum developers against building “copy-paste” EVM chains and superficial layer-2 connections, arguing that the ecosystem risks stagnation
Share
CryptoNews2026/02/05 17:53
Circle unveils CCTP V2 for seamless USDC crosschain transfers with Stellar

Circle unveils CCTP V2 for seamless USDC crosschain transfers with Stellar

The post Circle unveils CCTP V2 for seamless USDC crosschain transfers with Stellar appeared on BitcoinEthereumNews.com. Key Takeaways Circle’s CCTP V2 now supports the Stellar blockchain, allowing direct USDC transfers between Stellar and other networks. CCTP V2 eliminates the need for wrapped tokens or traditional bridges, reducing security risks in cross-chain transactions. Circle’s Cross-Chain Transfer Protocol Version 2 (CCTP V2) now supports Stellar, the decentralized blockchain platform designed for cross-border payments. Today’s integration enables seamless USDC transfers between Stellar and other blockchain networks. CCTP V2 allows users to move USD Coin, the stablecoin pegged 1:1 to the US dollar, across different blockchains without requiring wrapped tokens or traditional bridges that can introduce security risks. Source: https://cryptobriefing.com/circle-unveils-cctp-v2-for-usdc-crosschain-transfers-with-stellar/
Share
BitcoinEthereumNews2025/09/19 01:52
Vitalik: Calls for genuine innovation rather than replication, emphasizing consistency between words and deeds in the "connection with Ethereum."

Vitalik: Calls for genuine innovation rather than replication, emphasizing consistency between words and deeds in the "connection with Ethereum."

PANews reported on February 5th that Ethereum co-founder Vitalik Buterin stated that the current trend of creating numerous new EVM chains is simply copying the
Share
PANews2026/02/05 17:49